Beam Therapeutics
Most recent annual filing: 2026-02-24
- BEAM-304 PKU IND filing2026BEAM-304 PKU IND filing, 2026, material
- BEAM-301 readout2026BEAM-301 readout, 2026, material
- BEAM-304 IND filing2026BEAM-304 IND filing, 2026, notable
- BEAM-302 pivotal start2H 2026BEAM-302 pivotal start, 2H 2026, notable
- risto-cel BLA filingYear-End 2026risto-cel BLA filing, Year-End 2026, major
- BEAM-301 interimby the end of 2026BEAM-301 interim, by the end of 2026, material
- risto-cel manufacturing updateas early as year-end 2026risto-cel manufacturing update, as early as year-end 2026, notable
- BEAM-302 Ph1 readoutSep 5–9, 2026BEAM-302 Ph1 readout, Sep 5–9, 2026, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
BEAM-302
Nucleic Acid Target: SERPINA1, E342K
BEAM-304
Nucleic Acid Target: PAH, R408W
BEAM-301
Nucleic Acid Target: G6PC, R83C
BEAM-103
- Undisclosed indication
BEAM-102
- Undisclosed indication
Technology platforms
ESCAPE
Engineered Stem Cell Antibody Paired Evasion — non-genotoxic conditioning platform combining antibody-based conditioning with multiplex gene edited HSCs; applicable ex vivo or in vivo including for sickle cell disease
Targets: CD117
Base Editing Platform
Proprietary base editing technology enabling precision genetic medicines that target a single base in the genome without double-stranded DNA breaks, using CRISPR-guided deaminase enzymes. Supports ex vivo and in vivo delivery modalities across hematology and other disease areas including sickle cell disease and beta-thalassemia.
Apellis Complement Base Editing Collaboration · Apellis Pharmaceuticals
Research collaboration using Beam's base editing technology to discover treatments for complement system-driven diseases across six programs targeting specific genes in the complement system in various organs including the eye, liver, and brain. Apellis holds exclusive option rights to license any or all programs.
Biotech Distilled coverage (3)
- 2026-08-04 UPDATE: Beam Therapeutics (BEAM) - The Pivotal Cohort Opens, The Stock Doesn’t Care 🔒 Paid
- 2026-06-18 UPDATE: Beam Therapeutics (BEAM) - The Third Liver Bet Goes Clinical 🔒 Paid
- 2026-04-24 Beam Therapeutics (BEAM) - Scientific Deep Dive for Risto-cel and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.